Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 15/20 | 0.43 |
| ▸ | HTR2B | P41595 | 14/20 | 0.43 |
| ▸ | HTR2A | P28223 | 10/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3397701 | 0.84 | HTR2C (0.40) | HTR2CHTR2BHTR2AHTR6CYP2D6 | |
| Hydrochloric Acid SCHEMBL27828365 | 0.70 | HTR2C (0.42) | HTR2CHTR2BHTR2AHTR6 | |
| SCHEMBL4710814 | 0.70 | ALDH1A1 (0.41) | HTR2CHTR2BHTR2ACYP2D6SLC6A2 | |
| SCHEMBL13699524 | 0.69 | SLC6A2 (0.59) | HTR2CHTR2BHTR2ACYP2D6SLC6A2 | |
| SCHEMBL164537 | 0.69 | SLC6A2 (0.59) | HTR2CHTR2BHTR2ACYP2D6SLC6A2 | |
| Hydrochloric Acid SCHEMBL28210755 | 0.69 | KMT2A (0.41) | HTR2CHTR2BHTR2ACYP2D6SLC6A2 | |
| SCHEMBL28597186 | 0.69 | SLC6A2 (0.50) | HTR2CHTR2BHTR2AHTR6CYP2D6 | |
| Methyl Alcohol SCHEMBL28137463 | 0.69 | SLC6A2 (0.55) | HTR2CHTR2BHTR2ACYP2D6SLC6A2 | |
| SCHEMBL22489561 | 0.68 | HTR2C (0.41) | HTR2CHTR6CYP2D6 | |
| SCHEMBL5894706 | 0.68 | SLC6A2 (0.58) | HTR2CHTR2BHTR2ACYP2D6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | HTR2C 19/4885HTR2B 15/4885HTR2A 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.